Conquering Diseases

Study Of An Investigational Investigational Drug Combination For Metastatic Anal Cancer


Seeking men and women with untreated metastatic anal cancer for a study on whether adding an immune checkpoint inhibitor drug to the usual chemotherapy helps prevent the cancer from getting worse.


Participants in this study will either get 6 months of the standard chemotherapy alone or the investigational combination of the standard chemotherapy and the immune checkpoint inhibitor drug. After the 6 months of chemotherapy those who also received the immune checkpoint inhibitor drug can continue to get the drug for up to 2 years.

What we're hoping for

We are studying whether adding an immune checkpoint inhibitor drug to the standard chemotherapy treatment for metastatic anal cancer helps reduce symptoms and prevent cancer tumor growth.

Additional Information Identifier: NCT04444921

 Principal Investigator

Tasneem  Ali, MD

UMass Chan Medical School

 Study Contact

The Cancer  Research Office



UMass Chan University Campus

55 Lake Ave North 

Worcester,MA 01655